Prudential Financial Inc. lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 44.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 168,575 shares of the biopharmaceutical company's stock after selling 136,762 shares during the period. Prudential Financial Inc. owned about 0.11% of TG Therapeutics worth $5,074,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Blue Trust Inc. boosted its stake in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 371 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares during the period. Jones Financial Companies Lllp lifted its position in TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares in the last quarter. Synergy Asset Management LLC bought a new stake in TG Therapeutics during the fourth quarter valued at about $75,000. Finally, GAMMA Investing LLC increased its position in TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 2,171 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.
Insider Buying and Selling
In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the company. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $40.67.
Check Out Our Latest Stock Report on TGTX
TG Therapeutics Stock Down 1.2 %
Shares of TG Therapeutics stock traded down $0.48 during trading on Thursday, hitting $39.34. 2,457,640 shares of the stock traded hands, compared to its average volume of 3,075,549. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock's fifty day simple moving average is $34.94 and its 200 day simple moving average is $30.67. The firm has a market cap of $6.18 billion, a P/E ratio of -393.36 and a beta of 2.13. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
TG Therapeutics Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Featured Stories
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
